Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.67 |
| ▸ | MAOA | P21397 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | BCL2 | P10415 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | RECQL | P46063 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | APEX1 | P27695 | 3/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.67 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Athraquinones A SCHEMBL29373337 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL18614 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL21114402 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTMCL1MAOA | |
| SCHEMBL583089 | 0.80 | ADORA2A (0.53) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL4972786 | 0.80 | MAPT (1.00) | MEN1KMT2AMAPTMCL1MAOA | |
| Quinizarin SCHEMBL25194269 | 0.79 | MEN1 (0.95) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL11805858 | 0.78 | MAPT (0.96) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL22471867 | 0.78 | MAPT (0.96) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL3228431 | 0.78 | MAPT (0.96) | MEN1KMT2AMAPTMCL1MAOA | |
| Athraquinones A SCHEMBL7839563 | 0.78 | MAPT (0.96) | MEN1KMT2AMAPTMCL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074586-B1 | Process for the preparation of arylaminohydroxyanthraquinones | BAYER CHEMICALS AG (DE) | 2004-05-19 | — | — | EP | claimed |
| US-6420576-B1 | AMINATION OF ANTHRAQUINONE WITH AMINE IN SOLVENT | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-16 | — | — | US | claimed |
| US-11401234-B2 | Deuterated compounds and uses thereof | OncoTherics Ventures Limited (GB) | 2022-08-02 | — | — | US | disclosed |
| CN-109836343-B | Process for preparing phenylaminohydroxyanthraquinones | 朗盛德国有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20200270200-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | OncoTherics Ventures Limited (GB) | 2020-08-27 | — | — | US | disclosed |
| US-10385009-B2 | Deuterated compounds and uses thereof | BIOSTATUS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190161617-A1 | METHOD FOR PREPARING PHENYLAMINOHYDROXYANTHRAQUINONES | LANXESS DEUTSCHLAND GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
| EP-2882708-B1 | NEW COMPOUNDS AND USES THEREOF | BIOSTATUS LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| US-20150307441-A1 | NEW COMPOUNDS AND USES THEREOF | BIOSTATUS LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| EP-2882708-A1 | NEW COMPOUNDS AND USES THEREOF | Biostatus Limited (GB) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023956-A1 | NEW COMPOUNDS AND USES THEREOF | BIOSTATUS LIMITED (GB) | 2014-02-13 | — | — | WO | disclosed |
| US-6420576-B1 | AMINATION OF ANTHRAQUINONE WITH AMINE IN SOLVENT | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-16 | — | — | US | disclosed |
| WO-2001044190-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| JP-2001055519-A | PRODUCTION OF ARYLAMINOHYDROXYANTHRAQUINONES | BAYER AG | 2001-02-27 | — | — | JP | disclosed |
| CN-1283613-A | Method for prepn, of arylamino hydroxy anthraquinone | BAYER AG (DE) | 2001-02-14 | — | — | CN | disclosed |
| EP-1074586-A1 | Process for the preparation of arylaminohydroxyanthraquinones | BAYER AG (DE) | 2001-02-07 | — | — | EP | disclosed |
| EP-0450021-B1 | ANTI-CANCER COMPOUNDS | BRITISH TECH GROUP (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-5132327-A | ANTI-CANCER COMPOUNDS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-07-21 | — | — | US | disclosed |
| EP-0450021-A1 | ANTI-CANCER COMPOUNDS. | NAT RES DEV (GB) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005824-A1 | ANTI-CANCER COMPOUNDS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385009-B2 | Deuterated compounds and uses thereof | HIF1AN, HIF1A, EGLN2 | MEN1 2943/4885KMT2A 2099/4885MAPT 4842/4885 |
| US-11401234-B2 | Deuterated compounds and uses thereof | HIF1AN, HIF1A, EGLN2 | MEN1 2862/4885KMT2A 2124/4885MAPT 4837/4885 |
| US-20150307441-A1 | NEW COMPOUNDS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | MEN1 2915/4885KMT2A 2584/4885MAPT 4829/4885 |
| US-20200270200-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | MEN1 2862/4885KMT2A 2124/4885MAPT 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.